FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood Disorder

Loading...
Loading...

The FDA approved Agios Pharmaceuticals Inc's AGIO Pyrukynd (mitapivat) for hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

  • Pyruvate kinase deficiency is an inherited metabolic disorder of the enzyme pyruvate kinase that affects red blood cells' survival.
  • The company notes that Pyrukynd is a first-in-class, oral PK activator and the first approved disease-modifying therapy for this disease.
  • Pyrukynd is expected to be available in the U.S. approximately two weeks after approval. It is also under review by the European Medicines Agency for PK deficiency, with a decision expected by the end of 2022. 
  • Related: Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden.
  • The FDA approval is based on results from ACTIVATE and ACTIVATE-T studies.
  • In Phase 3 ACTIVATE trial, 40% of patients randomized to Pyrukynd achieved a hemoglobin response, compared to 0 patients randomized to placebo.
  • In Phase 3 ACTIVATE-T trial, mitapivat demonstrated a statistically significant and clinically meaningful reduction in transfusion burden for regularly transfused patients.
  • The company expects to initiate ACTIVATE-kids and ACTIVATE-kidsT – in pediatric patients with PK deficiency in mid-2022.
  • Price Action: AGIO shares closed 6.75% higher at $31.45 during after-hours trading on Thursday.
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefs
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...